Nov 17, 2020 · Therefore, this study suggests the GSK-LSD1 as a therapeutic agent for severe COVID-19 patients that are difficult to treat by directly targeting NF-κB. COVID-19 patients …

Nov 17, 2020 · Here, we applied a mechanism by which previously reported phosphorylated lysine-specific demethylase 1 (LSD1) stabilizes NF-κB p65 to control the expression of pro …

GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC 50 of 16 nM.

Gsk-lsd1 | C14H20N2 | CID 71522234 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity …

Nov 17, 2020 · GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro Signal Transduct Target Ther . 2020 Nov 17;5(1):267. doi: 10.1038/s41392 …

Lysine specific demethylase 1 (LSD1) is a histone demethylase found in various transcriptional co-repressor complexes. LSD1 is involved in ES cell differentiation, hematopoiesis, and has …

GSK-LSD1 is a potent and selective inhibitor of lysine specific demethylase 1 (LSD1). GSK-LSD1 potently inhibits proliferation of varies cancer cell lines by changing gene expression patterns. …

GSK LSD 1 dihydrochloride is a potent and selective lysine specific demethylase 1 (LSD1) inhibitor (IC 50 = 16 nM). Exhibits >1000-fold selectivity for LSD1 over closely related enzymes …

GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits …